Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 3, 2026CephalalgiaOpen Access

Atogepant for migraine in real-world clinical practice: Insights from a large multicentre study in a treatment-resistant population (GEMA project)

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAna Beatriz Gago-VeigaHospital Universitario de La PrincesaALAna Belen Lopez-RodriguezMJMarina Sanchez JimenezUniversidad Autónoma de Madrid

Discussion

Loading...

Member takes

Implication

Multicentre study shows atogepant reduces migraine days in treatment-resistant individuals, indicating promise for future therapies.

Key Points

  • This study evaluates the effectiveness and safety of atogepant for migraine prevention in patients with treatment-resistant migraine.
  • Prospective multicentre study across 15 Headache Units in Spain.
  • Collected demographic, clinical data, and headache metrics at baseline, 3 months, and 6 months.
  • Analyzed changes in monthly headache days (MHD) and monthly migraine days (MMD) as primary endpoints.
  • Median MHD decreased from 21 to 14 days and MMD from 14 to 8 days at 3 months (p < 0.0001).
  • 34% of patients achieved a ≥50% reduction in MHD, and 29% in MMD.
  • Adverse events were mild, with constipation (30%) and nausea (18%) being the most common.

Cite This Study

Gago-Veiga et al. (2026) studied this question.

synapsesocial.com/papers/69cf5d055a333a821460aa0fhttps://doi.org/10.1177/03331024261431337
View Full Paper
Ask AI
Bookmark
Share